维基百科
玛巴洛沙韦
玛巴洛沙韦,商品名速福达,是一种用于治疗甲型流感和乙型流感的抗病毒药物。[4]可将流感症状的持续时间缩短大约一天,但很容易筛选出耐药突变体病毒使其失效。[7]
臨床資料 | |
---|---|
商品名 | Xofluza |
其他名稱 | BXM (S-033188), BXA (S-033447) |
AHFS/Drugs.com | Monograph |
MedlinePlus | a618062 |
核准狀況 |
|
懷孕分級 | |
给药途径 | 口服给药 |
ATC碼 |
|
法律規範狀態 | |
法律規範 |
|
识别信息 | |
| |
CAS号 | 1985606-14-1 |
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
化学信息 | |
化学式 | C27H23F2N3O7S |
摩尔质量 | 571.55 g·mol−1 |
3D模型(JSmol) |
|
| |
|
玛巴洛沙韦为前驅药物,在人体内代谢时的中间产物“巴洛沙韦”(baloxavir acid, BXA)作为酶抑制剂,靶向作用于流感病毒的5′端帽依赖性核糖核酸内切酶并抑制其活性。[8]因此,其作用机制不同于奥司他韦等神经氨酸酶抑制剂和扎那米韦。[9]
玛巴洛沙韦最常见的副作用包括腹泻、支气管炎、恶心、鼻窦炎和头痛。[10]
2018年日本盐野义制药公司研发。瑞士罗氏制药公司买断后在全世界销售。[11]2018年在日本和美国获准临床使用[12][13][14]并作为口服单剂。[4]2021年4月在中国获批临床使用。
美国食品和药物管理局 (FDA) 认为可作为玛巴洛沙韦临床一线用药。[15]
参考文献 编辑
- ^ 1.0 1.1 Xofluza Australian prescription medicine decision summary. Therapeutic Goods Administration (TGA). 2 March 2020 [16 August 2020]. (原始内容于13 March 2020).
- ^ Xofluza Product information. Health Canada. 25 April 2012 [29 May 2022]. (原始内容于12 August 2022).
- ^ Summary Basis of Decision (SBD) for Xofluza. Health Canada. 23 October 2014 [29 May 2022]. (原始内容于31 May 2022).
- ^ 4.0 4.1 4.2 Xofluza- baloxavir marboxil tablet, film coated. DailyMed. 28 October 2019 [9 January 2020]. (原始内容于28 October 2020).
- ^ Xofluza EPAR. European Medicines Agency (EMA). 9 November 2020 [25 January 2021]. (原始内容于30 January 2021). Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ Xofluza Product information. Union Register of medicinal products. [3 March 2023]. (原始内容于2023-03-05).
- ^ Baloxavir Marboxil for Uncomplicated Influenza: Mechanism of Action & Side Effects. Huateng Pharma. [29 May 2020]. (原始内容于24 February 2021).
- ^ Noshi T, Kitano M, Taniguchi K, Yamamoto A, Omoto S, Baba K, et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res. December 2018, 160: 109–117. PMID 30316915. doi:10.1016/j.antiviral.2018.10.008 .
- ^ O'Hanlon, Ryan; Shaw, Megan L. Baloxavir marboxil: the new influenza drug on the market. Current Opinion in Virology. April 2019, 35: 14–18 [28 September 2020]. ISSN 1879-6265. PMID 30852344. S2CID 73726080. doi:10.1016/j.coviro.2019.01.006. (原始内容于4 November 2021).
- ^ FDA Expands Approval of Influenza Treatment to Post-Exposure Prevention (新闻稿). U.S. Food and Drug Administration (FDA). 23 November 2020 [23 November 2020]. (原始内容于23 November 2020). 该来源属于公有领域,本文含有该来源内容。
- ^ Branswell H. A flu drug — shown to reduce the duration of symptoms — could upend treatment in U.S. . Stat. 27 June 2018 [28 June 2018]. (原始内容于20 October 2020).
- ^ FDA approves new drug to treat influenza (新闻稿). U.S. Food and Drug Administration (FDA). 24 October 2018 [23 October 2019]. (原始内容于24 October 2019). 该来源属于公有领域,本文含有该来源内容。
- ^ Drug Approval Package: Xofluza Film-Coated Tablets (Baloxavir marboxil). U.S. Food and Drug Administration (FDA). 7 December 2018 [10 May 2020]. (原始内容于26 July 2020). 该来源属于公有领域,本文含有该来源内容。
- ^ FDA Approval Package for 210854Orig1s001 (PDF). U.S. Food and Drug Administration (FDA). 16 October 2019 [30 September 2020]. (原始内容 (PDF)于9 April 2021). 该来源属于公有领域,本文含有该来源内容。
- ^ New Drug Therapy Approvals 2018 (PDF) (报告). U.S. Food and Drug Administration (FDA). January 2019 [16 September 2020]. (原始内容于17 September 2020). 该来源属于公有领域,本文含有该来源内容。